A pan-cancer analysis revealed that compared to normal tissues, significantly elevated mRNA expression levels of SYNGR2 were observed in 26 cancers, including BLCA, BRCA, CESC, and other tumor tissues. This evidence concerns the gene SYNGR2 and cancer.